top of page
CROPPED-Marta Schilling.jpg
  • LinkedIn

Marta Shilling

cGMP Manufacturing and Development

Career Highlights

Marta brings over 30 years of experience in cell and gene therapies specializing in cGMP manufacturing and development. 

  • Baxter Healthcare (later Nexell Therapeutics)

    • Involved in the research, development, and customer support of the Isolexâ CD34 Cell Selection System and the CytoMateâ Cell Washer Device, supporting customers throughout the United States, Canada, Europe and Australia in development of their cell therapy programs.

  • IDM Pharma - Associate Director of the Cell Processing Laboratory

    • Instrumental in setting up the cGMP manufacturing facility and systems.

    • One of the primary contributors to significant process improvements for producing IDM’s autologous dendritic cell vaccines in Phase I/II clinical trials.

  • Progenitor Cell Therapy - Senior Director, Manufacturing Operations/Technical Director

    • Oversaw Operations at the Mountain View, CA, Contract Development Manufacturing Organization (CDMO) focusing exclusively on cell & gene therapies on behalf of their clients.  

  • Prima BioMed - Vice President, Manufacturing

    • Oversee Chemistry Manufacturing and Controls (CMC) and cGMP manufacturing for the lead clinical candidate, CvacÔ, an autologous dendritic cell product in a global Phase II/III development in USA, Europe and Australia. Marta

    • Successfully ensured harmonization and established comparability between the manufacturing processes across the three geographies at the CDMOs.

  • ImmunoCellular Therapeutics (IMUC) - Vice President, Cell Therapy Manufacturing

    • Oversee CMC for their product pipeline including a Phase III autologous dendritic cell therapy for treatment of newly diagnosed glioblastoma in N. America and Europe.


Bachelor of Science degree in Medical Technology, specializing in Hematology from the University of Vermont

bottom of page